Modern, in red numbers. The American biotechnological company has recorded losses of 1,301 million dollars in the first half of the year, compared to profits of 5,854 million dollars in the same period a year ago. The company has attributed the fall in its net result to the slowdown in the marketing of the Covid-19 vaccine, according to the financial statements made public this Thursday by the company.
Moderna’s billing has plummeted in the first six months of the year, with a drop of 79.6%. The biotechnological company has entered 2,206 million dollars, compared to 10,815 million dollars in the same period a year ago. “Second quarter sales were on target given the seasonal nature of Covid-19”, has pointed out Stéphane Bancel, CEO of Moderna. In the second quarter alone, Moderna’s sales fell 93%, to $344 million.
“I am pleased with the progress made by our commercial team in the United States to secure new contracts for the fall of 2023”, added the manager. Starting this fall, pharmaceutical companies will market Covid-19 vaccines directly with health centers, not with countries. “We are on track to achieve sales in 2023 of between 6,000 and 8,000 million dollars, depending on the vaccination rates with Covid in the United StatesBancel has announced.
Moderna expects to invoice up to 8,000 million dollars for the Covid-19 vaccine until the end of the year
Of the $6 billion the company expects to bill from Covid-19 vaccines, $4 billion will come from existing deals, while between $2 billion and $4 billion come from additional sales in the United States, Japan, the European Union (EU) and other countries. Approximately, 30% of sales will occur in the third quarter, while the remaining 70% will occur in the fourth quarter.
In the second quarter of the year, The company has increased its research and development (R&D) expenses by 62% to 1,148 million dollars. Bancel has assured that Moderna’s clinical project portfolio is running “at full speed”, with four vaccines against infectious diseases in phase 3, so the products will surely be launched throughout 2024, 2025 and 2026.
Moderna closed 2022 with a profit of 8,362 million dollars, 31% less than in 2021. The total income of the American biotech in 2022 was 19,263 million dollars, compared to 18,471 million dollars in 2021.
2023-08-03 16:42:25
#Moderna #enters #losses #semester #fall #Covid19 #vaccine
